Additionally, research has indicated that CD40 agonists can enhance the effectiveness of immune checkpoint inhibitors, such as anti-PD1 and anti-CTLA4, in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The gene discussed is CD40; the disease is pancreatic ductal adenocarcinoma.